+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.

Age: 18Years - 60YearsAll GendersPhase 3
90 locations
C

Actively Recruiting

Researchers are studying relapsing multiple sclerosis RMS in this Phase 3b trial to compare the effects of switching from the drug ocrelizumab to remibrutinib versus continuing ocrelizumab treatment. The goal is to assess whether remibrutinib is similarly effective, safe, and tolerable for people living with RMS. This study is randomized, open-label, and conducted across multiple centers globally, including the USA. Participants will be randomly assigned to either switch to oral remibrutinib daily or continue their standard ocrelizumab treatment, which is given by infusion or injection. The study includes an initial Core Part lasting up to 24 months, during which efficacy and safety are closely monitored. After completing this phase, eligible participants may join an Extension Part of up to 24 months where all receive remibrutinib in an open-label format. During the study, participants will undergo regular assessments including MRI scans to measure new or enlarging brain lesions, neurological evaluations, and monitoring for adverse events. Researchers will track disease activity, safety, and tolerability throughout both study parts. The total participation time may be up to 48 months, providing long-term data on remibrutinib following ocrelizumab treatment.

Age: 40Years - 70YearsAll GendersPhase 3
131 locations
L

Actively Recruiting

Healthy Volunteer

Pregnancy involves many changes in the cardiovascular system, but in pre-eclampsia PE, these changes are abnormal. PE affects 5 to 8 percent of pregnant women worldwide and is marked by high blood pressure and protein in the urine after 20 weeks of pregnancy. If not treated, PE can cause serious problems for both mother and baby. This research focuses on better monitoring and early detection of PE in high-risk pregnant women. The study compares two groups a control group receiving no intervention, and a remote monitoring group using special devices. At 10 weeks of pregnancy, all participants receive measurements with NICCOMO, maternal venous Doppler echography, and Maltron bio-electronic impedance analysis. These tests repeat at 20 weeks, and at 30 weeks if results are abnormal. The remote monitoring group uses devices to check blood pressure twice daily, activity continuously, and weight once daily. Participants will be monitored throughout their pregnancy with repeated tests and device tracking. Researchers will check blood pressure, heart and vein function, body measurements, activity levels, and weight at specific times. They will also collect birth-related information like birth weight, gestational age, delivery method, and timing. The study includes 2000 pregnant women and aims to improve follow-up and care for those at risk of PE.

Age: 18Years - 50YearsFEMALEPhase Not Applicable
8 locations
R

Actively Recruiting

Researchers are conducting a Phase 3, randomized, open-label study comparing two ways of giving the drug frexalimabby subcutaneous under the skin injection every 4 weeks versus intravenous IV infusion every 4 weeksin adults aged 18 to 60 years with relapsing multiple sclerosis RMS or non-relapsing secondary progressive multiple sclerosis nrSPMS. The study aims to evaluate the pharmacokinetics, safety, and efficacy of these two administration methods in this population. Participants will receive frexalimab either through an IV infusion or by subcutaneous injection using an on-body delivery system OBDS, with the option for home self-administration starting after appropriate training in Part B of the study. The treatment period for Parts A and B combined lasts 48 weeks 12 months, with an optional Part C continuing until a long-term safety study begins. Scheduled visits occur monthly between weeks 4 and 24, then every 1 to 3 months in Part B, and every 6 months in Part C. Participants discontinuing treatment early will have additional follow-up visits. During the study, participants will undergo regular on-site visits for drug administration and monitoring. Researchers will collect blood samples to assess drug levels and immune responses, perform MRI scans to track brain lesions, and monitor safety through adverse event reporting and laboratory tests. The studys main outcomes include drug concentration measurements up to week 24 and safety and efficacy assessments up to week 96. Follow-up after treatment ends will continue for 6 months to observe any ongoing effects.

Age: 18Years - 60YearsAll GendersPhase 3
68 locations